Table 1. (GI %) Percentage Growth Inhibition Resulting from Compounds’ Concentration of 10 μM (4, 12–23) of Subpanel Tumor Cell Linesa.
| subpanel tumor cell lines (sample conc. = 10 μM) | % growth
inhibition (GI %) |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 | 12 | 13 | 14 | 15 | 16 | 18 | 19 | 20 | 22 | 23 | |
| leukemia | |||||||||||
| CCRF-CEM | 36 | 7 | 10 | 7 | 11 | 12 | 30 | 22 | 54 | 24 | 30 |
| HL-60(TB) | 30 | 3 | 8 | 13 | 12 | 9 | – | 22 | – | – | 14 |
| RPMI-8226 | 53 | 7 | 2 | – | 9 | 16 | 7 | 9 | 34 | 44 | 34 |
| SR | 38 | 15 | 22 | 11 | 24 | 12 | 16 | 17 | 89 | 62 | 78 |
| non-small-cell lung cancer | |||||||||||
| HOP-62 | – | 27 | 18 | – | 53 | 7 | – | – | 80 | 47 | 79 |
| HOP-92 | 100 | 6 | 8 | 18 | 20 | 13 | – | – | 18 | 27 | 50 |
| A549/ATCC | 15 | 19 | – | 8 | 34 | 6 | 9 | 2 | 91 | 73 | 94 |
| EKVX | 21 | 15 | 19 | 18 | 13 | 13 | 21 | 20 | 30 | 53 | |
| NCI-H460 | 31 | 26 | 15 | 10 | 52 | 6 | 4 | – | 90 | 81 | 99 |
| NCI-H522 | 42 | 19 | 20 | 15 | 32 | 20 | 20 | 24 | 56 | 47 | 79 |
| NCI-H322M | 30 | 12 | 15 | 10 | 23 | 11 | – | 3 | 33 | 21 | 56 |
| NCI-H23 | 31 | 46 | 1 | 1 | 26 | 5 | 3 | 2 | 63 | 46 | 71 |
| colon cancer | |||||||||||
| HCC-2998 | 3 | – | – | 6 | 18 | – | – | – | – | 3 | 61 |
| HCT-116 | 30 | 16 | - | 9 | 49 | 23 | 3 | 3 | 126 | 96 | 93 |
| COLO 205 | – | 1 | – | 2 | 18 | – | – | – | 62 | 11 | 67 |
| HCT-15 | 33 | 6 | 3 | 6 | 15 | 8 | 3 | 15 | 52 | 47 | 57 |
| HT29 | – | 8 | 2 | – | 22 | 2 | – | – | 74 | 68 | 55 |
| KM12 | 28 | – | 6 | 13 | 11 | 9 | – | – | 58 | 53 | 62 |
| SW-620 | 1 | 5 | 9 | 1 | 19 | 6 | – | – | 47 | 48 | 73 |
| CNS cancer | |||||||||||
| SF-268 | 11 | 2 | 12 | 4 | 29 | 10 | – | – | 92 | 56 | 63 |
| SF-295 | 13 | 32 | 6 | 2 | 23 | 11 | 7 | 7 | 84 | 24 | 81 |
| SF-539 | 8 | 5 | 2 | – | 25 | – | – | – | 139 | 99 | 66 |
| SNB-75 | 14 | 15 | 18 | 3 | 89 | 7 | – | – | 165 | 94 | 102 |
| U251 | 23 | 16 | 19 | 18 | 47 | 6 | – | 5 | 93 | 51 | 95 |
| melanoma | |||||||||||
| LOX IMVI | 16 | 6 | 8 | 3 | 21 | 21 | 40 | 16 | 63 | 24 | 63 |
| MALME-3 | 28 | 9 | 1 | 4 | 23 | 5 | – | 28 | 89 | 26 | 65 |
| M14 | 7 | 6 | 4 | 6 | 25 | 15 | – | 7 | 49 | 29 | 54 |
| MDA-MB-435 | 12 | 3 | 1 | – | 23 | 10 | – | 12 | 40 | 28 | 67 |
| SK-MEL-2 | 34 | – | – | – | 10 | 3 | 3 | 34 | 9 | 10 | 22 |
| SK-MEL-28 | 15 | – | – | – | 16 | – | – | 15 | 52 | 26 | 53 |
| SK-MEL-5 | 57 | 4 | 3 | 5 | 12 | 9 | 9 | – | 50 | 33 | 54 |
| UACC-257 | 30 | 9 | 6 | 10 | 11 | 3 | – | 30 | 26 | 34 | 36 |
| UACC-62 | 52 | 13 | 15 | 8 | 26 | 8 | 45 | 52 | 17 | 35 | 92 |
| ovarian cancer | |||||||||||
| 786-0 | 7 | 5 | 7 | 7 | 29 | – | – | – | 36 | 20 | 55 |
| A498 | 50 | 20 | 9 | 6 | 15 | 1 | 45 | 11 | 17 | 65 | |
| ACHN | 15 | 33 | 16 | 15 | 48 | 10 | 3 | 17 | 74 | 20 | 75 |
| CAKI-1 | 21 | 29 | 8 | – | 49 | 32 | 14 | 24 | 113 | 41 | 91 |
| RXF 393 | 16 | 16 | 27 | 13 | 34 | 6 | – | 95 | 39 | 106 | |
| SN12C | 45 | 12 | 34 | 28 | 16 | 12 | 23 | 26 | 84 | 34 | 44 |
| prostate cancer | |||||||||||
| PC-3 | 57 | 55 | 17 | 10 | 27 | 25 | 6 | 14 | 55 | 62 | 123 |
| DU-145 | 9 | 1 | 5 | 4 | 61 | 2 | – | – | 113 | 101 | 77 |
| breast cancer | |||||||||||
| MCF7 | 30 | 14 | 11 | 15 | 27 | 21 | 1 | 17 | 74 | 55 | 65 |
| MDA-MB-231/ATCC | 21 | 25 | 10 | 7 | 50 | 25 | 9 | 24 | 126 | 49 | 57 |
| HS 578T | 9 | 18 | – | – | 61 | 2 | – | – | 113 | 101 | 77 |
| BT-549 | 6 | – | – | – | 3 | – | 2 | 11 | 52 | 62 | 29 |
| T-47D | 12 | 61 | 15 | 12 | 24 | 19 | 17 | 17 | 84 | 36 | 39 |
| MDA-MB-468 | 29 | 17 | 3 | – | 44 | – | – | – | 103 | 81 | 74 |
| MG-MID | 25 | 11 | 8 | 6 | 28 | 9 | 2 | 5 | 65 | 44 | 62 |
a
– represents GI ≤ 10%. Bold numbers represent the high % GI. Underlined numbers represent GI ≥100% “Lethal activity”. MG-MID represents full-panel mean-graph midpoint.